Inicio>>Signaling Pathways>> GPCR/G protein>> CXCR>>CXCR2-IN-1

CXCR2-IN-1

Catalog No.GC31754

CXCR2-IN-1 es un antagonista de CXCR2 que penetra en el sistema nervioso central con una pIC50 de 9,3.

Products are for research use only. Not for human use. We do not sell to patients.

CXCR2-IN-1 Chemical Structure

Cas No.: 1873376-49-8

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
337,00 $
Disponible
1mg
138,00 $
Disponible
5mg
321,00 $
Disponible
10mg
552,00 $
Disponible
25mg
1.103,00 $
Disponible
50mg
1.792,00 $
Disponible
100mg
3.126,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

CXCR2-IN-1 is a central nervous system penetrant CXCR2 antagonists with a pIC50 of 9.3.

CXCR2 plays an important role in the activation and recruitment of neutrophils to sites of inflammation. CXCR2-IN-1 shows favorable central nervous system penetration property (Br/Bl>0.45)[1].

CXCR2-IN-1 shows efficacy in a cuprizone-induced demyelination model through oral administration, providing evidence to support CXCR2 to be a potential therapeutic target to treat demyelinating diseases such as multiple sclerosis[1].

[1]. Xu H, et al. Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders. ACS Med Chem Lett. 2016 Feb 8;7(4):397-402.

Reseñas

Review for CXCR2-IN-1

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CXCR2-IN-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.